Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Rick Strange who wrote (407)	1/9/1999 12:04:00 AM
From: Ariella	Read Replies (1) \| Respond to of 1386

Hi Rick - To the best of my knowledge, LE-T remains on schedule for NDA by mid-year 1999. As for BOL payments, here's what it says in last year's 10-K: Through December 31, 1997, Bausch and Lomb has provided the Company with $5 million in cash advances against future sales. An additional $1 million is due upon the receipt of regulatory approval for LE-T in the United States. Bausch & Lomb will be entitled to credits against future purchases or sales of the active drug substance based on the advances made, until all the advances have been repaid. -Ariella